JSE-listed pharmaceutical company Adcock Ingram reports that, owing to an improvement in the trading environment, its earnings a share and headline earnings a share for the six months to December 31 are likely to be 37.3c higher than the 186.5c reported for the six months ended December 31, 2020.
Adcock experienced improved demand for its over-the-counter and consumer healthcare products during the prior under review.
There was also no recurrence of the retrenchments costs incurred in the six months to December 31, 2020.